In-vivo pharmacokinetics, tissue distribution and anti-tumour effect of hydroxycamptothecin delivered in oil-in-water submicron emulsions

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 6, 2012, Pages 783-791

  Zhao, Yong Xing ^a,b   Liu, Dan Xing ^a   Liang, Wen Quan ^b   Ye, Zhi Wei ^c  

^a ZHENGZHOU UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c KAROLINSKA INSTITUTE   (Sweden)

Author keywords

hydroxycamptothecin; pharmacokinetics; submicron emulsions; tissue distribution; tumour targeting

Indexed keywords

ANTINEOPLASTIC ALKALOID; HYDROXYCAMPTOTHECIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANIONIC SUBMICRON EMULSION; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER INHIBITION; CATIONIC SUBMICRON EMULSION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SELECTIVITY; DRUG TARGETING; EMULSION; IN VIVO STUDY; MALE; MEAN RESIDENCE TIME; MOUSE; NONHUMAN; RAT; SARCOMA; TISSUE DISTRIBUTION;

ANIMALS; ANIONS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECA; CAMPTOTHECIN; CATIONS; DRUG CARRIERS; EMULSIONS; INJECTIONS, INTRAVENOUS; MALE; MICE; MICE, INBRED STRAINS; NEOPLASMS; OILS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION; WATER;

EID: 84861096499     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01484.x     Document Type: Article

References (24)

1. Reddy PR, Venkateswarlu V,. Pharmacokinetics and tissue distribution of etoposide delivered in long circulating parenteral emulsion. J Drug Target 2005; 13: 543-553. (Pubitemid 43101953)
2. Goldstein D, et al,. Influence of oil droplet surface charge on the performance of antibody-emulsion conjugates. Biomed Pharmacother 2007; 61: 97-103. (Pubitemid 46185871)
3. Shi CY, Benita S,. Enhanced absorption and drug targeting by positively charged submicron emulsions. Drug Dev Res 2000; 50: 476-486.
4. Hsiang YH, et al,. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260: 14873-14878.
5. Rothenberg ML,. Topoisomerase I inhibitors: review and update. Ann Oncol 1997; 8: 837-855. (Pubitemid 27452081)
6. Hertzberg RP, et al,. Modification of the hydroxy lactone ring of camptothecin: inhibition of mammalian topoisomerase I and biological activity. J Med Chem 1989; 32: 715-720. (Pubitemid 19075732)
7. Zhao YX, et al,. Preparation and cytotoxic activity of hydroxycamptothecin nanosuspensions. Int J Pharm 2010; 392: 64-71.
8. Hong M, et al,. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J Control Release 2009; 133: 96-102.
9. Yang X, et al,. Preparation, pharmacokinetics and tissue distribution of micelles made of reverse thermo-responsive polymers. Int J Pharm 2009; 370: 210-215.
10. Zhang C, et al,. Polymeric micelle systems of hydroxycamptothecin based on amphiphilic N-alkyl-N-trimethyl chitosan derivatives. Colloids Surf B Biointerfaces 2007; 55: 192-199. (Pubitemid 46274240)
11. Zhao YX, et al,. Enhanced nuclear delivery and cytotoxic activity of hydroxycamptothecin using o/w emulsions. J Pharm Pharm Sci 2007; 10: 61-70.
12. Yang J, et al,. Application of liposome-encapsulated hydroxycamptothecin in the prevention of epidural scar formation in New Zealand white rabbits. Spine J 2011; 11: 218-223.
13. Min KH, et al,. Hydrophobically modified glycol chitosan nanoparticles-encapsulated camptothecin enhance the drug stability and tumor targeting in cancer therapy. J Control Release 2008; 127: 208-218.
14. Li Q, et al,. Preparation, characterization and targeting of micronized 10-hydroxycamptothecin-loaded folate-conjugated human serum albumin nanoparticles to cancer cells. Int J Nanomedicine 2011; 6: 397-405.
15. Zhao YX, et al,. Cationic submicron emulsions overcome multidrug resistance in SGC7901/VCR cells. Pharmazie 2011; 66: 130-135.
16. Klang SH, et al,. Physicochemical characterization and acute toxicity evaluation of a positively-charged submicron emulsion vehicle. J Pharm Pharmacol 1994; 46: 986-993.
17. Yue PF, et al,. Development and optimization of intravenous puerarin emulsions formation by a novel complex-phase inversion-homogenization technology. Chem Pharm Bull 2007; 55: 1563-1568.
18. Liu Q, et al,. Comparison between sonodynamic effect with protoporphyrin IX and hematoporphyrin on sarcoma 180. Cancer Chemother Pharmacol 2007; 60: 671-680. (Pubitemid 47247279)
19. Yamaguchi T, et al,. Distribution of prostaglandin E1 in lipid emulsion in relation to release rate from lipid particles. Chem Pharm Bull 1994; 42: 646-650. (Pubitemid 24156286)
20. Hultin M, et al,. Intravenous lipid emulsions: removal mechanisms as compared to chylomicrons. J Lipid Res 1995; 36: 2174-2184.
21. Sengupta S, et al,. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies. Pharmacol Res 2000; 42: 459-464.
22. Thurston G, et al,. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998; 101: 1401-1413. (Pubitemid 28166838)
23. Yuan F, et al,. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-3756.
24. Krasnici S, et al,. Effect of the surface charge of liposomes on their uptake by angiogenic tumor vessels. Int J Cancer 2003; 105: 561-567. (Pubitemid 36578564)